
Mohamed Elmeliegy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7097408/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies. Clinical Pharmacokinetics, 2020, 59, 699-714.	1.6	150
2	Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncology, 2022, 18, 425-436.	1.1	28
3	Discordance Between Childâ€Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds. Journal of Clinical Pharmacology, 2021, 61, 105-115.	1.0	19
4	Exposureâ€Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations in the EMBRACA and ABRAZO Trials. Journal of Clinical Pharmacology, 2020, 60, 1334-1343.	1.0	12
5	Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2019, 37, 5076-5076.	0.8	11
6	Talazoparib Exposureâ€Efficacy Analysis in Patients With Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations in the EMBRACA Trial. Journal of Clinical Pharmacology, 2020, 60, 1324-1333.	1.0	10
7	Considerations on the Calculation of the Human Equivalent Dose from Toxicology Studies for Biologic Anticancer Agents. Clinical Pharmacokinetics, 2021, 60, 563-567.	1.6	9
8	Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2020, 86, 325-337.	1.1	4
9	Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations. Clinical Pharmacology and Therapeutics, 2021, , .	2.3	3